4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
MedKoo(授权代理)
主营:主营:抗癌化学试剂和激酶抑制剂
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > peptide > 梅德库/CGP52421/1/406204
商品详细梅德库/CGP52421/1/406204
梅德库/CGP52421/1/406204
梅德库/CGP52421/1/406204
商品编号: 406204
品牌: MedKoo
市场价: ¥0.00
美元价: 0.00
产地: 美国(厂家直采)
公司:
产品分类: 多肽合成
公司分类: peptide
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍

CGP52421

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#:406204

CAS#:179237-49-1

Description:CGP52421 is a FLT3 inhibitor, which is also an metabolite of midostaurin (PKC412).

Price and Availability

SizePriceShipping out timeQuantity
Inquire bulk and customized quantity

Pricing updated 2021-01-23.Prices are subject to change without notice.

CGP52421, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406204Name: CGP52421CAS#: 179237-49-1Chemical Formula: C36H32N4O5Exact Mass: 600.23727Molecular Weight: 600.66Elemental Analysis: C, 71.98; H, 5.37; N, 9.33; O, 13.32

Synonym:CGP52421; CGP-52421; CGP 52421.

IUPAC/Chemical Name:N-((5S,7S,8S,10R)-15-hydroxy-8-methoxy-10-methyl-17-oxo-6,7,8,9,10,15,16,17-octahydro-5H-18-oxa-4b,10a,16-triaza-5,10-methanodibenzo[b,h]cyclodeca[jkl]cyclopenta[e]-as-indacen-7-yl)-N-methylbenzamide

InChi Key:WMQSFYBLPAXEDG-VPROBEFOSA-N

InChi Code:InChI=1S/C36H32N4O5/c1-36-18-25(44-3)24(38(2)35(43)19-11-5-4-6-12-19)17-26(45-36)39-22-15-9-7-13-20(22)27-29-30(34(42)37-33(29)41)28-21-14-8-10-16-23(21)40(36)32(28)31(27)39/h4-16,24-26,34,42H,17-18H2,1-3H3,(H,37,41)/t24-,25-,26-,34?,36+/m0/s1

SMILES Code:O=C(N([C@H]1C[C@@](O2)([H])N3C4=CC=CC=C4C5=C3C6=C(C7=CC=CC=C7N6[C@@]2(C)C[C@@H]1OC)C(C(O)N8)=C5C8=O)C)C9=CC=CC=C9

Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Additional Information

References

1: Yin OQ, Wang Y, Schran H. A mechanism-basedpopulation pharmacokinetic model for characterizing time-dependentpharmacokinetics of midostaurin and its metabolites in human subjects.Clin Pharmacokinet. 2008;47(12):807-16. doi:10.2165/0003088-200847120-00005. PubMed PMID: 19026036.

2: Wang Y, Yin OQ, Graf P, Kisicki JC, Schran H. Dose- andtime-dependent pharmacokinetics of midostaurin in patients with diabetesmellitus. J Clin Pharmacol. 2008 Jun;48(6):763-75. doi:10.1177/0091270008318006. PubMed PMID: 18508951.

3: Illmer T, Thiede HM, Thiede C, Bornhäuser M, Schaich M, Schleyer E,Ehninger G. A highly sensitive method for the detection of PKC412(CGP41251) and its metabolites by high-performance liquidchromatography. J Pharmacol Toxicol Methods. 2007 Jul-Aug;56(1):23-7.Epub 2007 Feb 23. PubMed PMID: 17395497.

4: Levis M, Brown P, Smith BD, Stine A, Pham R, Stone R, Deangelo D,Galinsky I, Giles F, Estey E, Kantarjian H, Cohen P, Wang Y, Roesel J,Karp JE, Small D. Plasma inhibitory activity (PIA): a pharmacodynamicassay reveals insights into the basis for cytotoxic response to FLT3inhibitors. Blood. 2006 Nov 15;108(10):3477-83. Epub 2006 Jul 20. PubMedPMID: 16857987; PubMed Central PMCID: PMC1895426.

品牌介绍
MedKoo 美帝药库公司以药物化学合成技术为核心,密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向,不断推出抗癌化合物新品种。 。 美帝药库MedKoo将在中国建立药物化学合成生产基地和多个现代化药物化合物存储仓库。 美帝药库的药物化合物来源于以下几个渠道:自主合成、委托化学合成、合作伙伴、和从国内外市场上选购。 MedKoo美帝药库的抗癌分子库 MedKoo的目标是打造全球规模最大、品种最多、类别最全和质量最好的小分子抗癌化合物库。MedKoo的抗癌药库将由下列5个分子库组成: (1)上市抗癌药库:该库将含有大约100个全球已批准上市的小分子抗癌化合物; (2)抗癌候选药物库:该分子库含有大约400个世界各国正在临床研究中抗癌小分子候选药物; (3)同系抗癌分子库:该分子库将含有多个化学结构类似或抗癌机制类似的分子包; (4)抗癌分子预制模块库:该库主要含有用于组建抗癌目标分子的分子模块包; (5)同位素标记抗癌分子库。